MedTrace Logo

Cross-linked CMC and Silk Proteins in Corneal Re-epithelization

NCT06840990 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 20

Last updated 2025-03-07

No results posted yet for this study

Summary

Data analyses and revision of the corneal re-epithelization in patients who underwent either PRK (Photorefractive Keratectomy), CXL (Corneal Cross-Linking), PTK (phototherapeutic keratectomy), or experienced a corneal abrasion. A novel ophthalmic solution containing cross-linked CMC (CX-CMC) and Silk Proteins (SP) has been made available on the market. Both molecules have been widely studied for their wound healing properties in the ophtalmic field. This new ophthalmic solution is the first on the market formulated with a CX-CMC and SP.

Conditions

  • Corneal Epithelial Wound Healing

Interventions

DEVICE

CXC-SP

Standard therapy plus sterile Isotonic ophthalmic solution based on CX-CMC and silk protein, istilled six time a day until complete healing.

DEVICE

CTRL

Standard therapy plus sterile ophtalmic isotonic solution for six time a day until complete healing.

Sponsors & Collaborators

  • San Giovanni Addolorata Hospital

    collaborator OTHER

  • D&V FARMA srl

    lead INDUSTRY

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-01-01
Primary Completion
2024-05-01
Completion
2024-06-01

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06840990 on ClinicalTrials.gov